结核病高剂量利福平的个体化给药算法与个性化治疗
研究提出适用于高剂量利福平贝叶斯剂量优化的暴露目标,并利用实测血药浓度结合贝叶斯预测算法预测未来剂量,考虑自身诱导、饱和药代动力学及高 occasion 间变异。建议的暴露目标为稳态 AUC0-24h 181-214 h×mg/L;根据该目标预测的患者 optimal 剂量范围为 1200-3000 mg(20-50 mg/kg),众数 1800 mg(30 mg/kg,n=24)。
要点
- 建议的贝叶斯剂量优化暴露目标为稳态 AUC0-24h 181-214 h×mg/L。
- 预测 optimal 剂量范围 1200-3000 mg(20-50 mg/kg),众数 1800 mg(30 mg/kg,n=24)。
- 考虑 MIC 时预测剂量高度依赖 MIC 测量技术变异,且剂量显著低于仅用 AUC 目标时。
核心结论
- 研究推导了适用于高剂量利福平贝叶斯剂量优化的新暴露目标。
- 利用实测血药浓度结合贝叶斯预测可预测未来剂量,并考虑利福平的自身诱导、饱和药代动力学及高 occasion 间变异。
研究设计与样本
- 基于文献中利福平药代动力学与安全性及抗分枝杆菌活性的数据定义贝叶斯剂量优化暴露目标。
- 对接受利福平 10 mg/kg 治疗的患者,利用稀疏血药浓度监测和基线利福平 MIC,结合贝叶斯预测算法预测个体 optimal 剂量。
主要发现
- 建议的暴露目标为稳态 AUC0-24h 181-214 h×mg/L。
- 观察到的 MIC 范围为 0.016-0.125 mg/L(众数 0.064 mg/L)。
- 使用建议目标预测的患者 optimal 剂量范围为 1200-3000 mg(20-50 mg/kg),众数 1800 mg(30 mg/kg,n=24)。
- 考虑 MIC 时预测的 optimal 剂量高度依赖实测个体 MIC 的已知技术变异,且剂量显著低于仅使用 AUC0-24h 目标时。
关键数值与推荐
- 贝叶斯剂量优化暴露目标:稳态 AUC0-24h 181-214 h×mg/L。
- 观察到的 MIC 范围:0.016-0.125 mg/L(众数 0.064 mg/L)。
- 预测 optimal 剂量范围:1200-3000 mg(20-50 mg/kg),众数 1800 mg(30 mg/kg,n=24)。
临床怎么用
- 临床可基于稳态 AUC0-24h 181-214 h×mg/L 的目标,利用稀疏血药浓度监测和贝叶斯预测算法个体化调整高剂量利福平剂量。
- 考虑 MIC 信息时需注意 MIC 测量技术变异对剂量预测的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To propose new exposure targets for Bayesian dose optimisation suited for high-dose rifampicin and to apply them using measured plasma concentrations coupled with a Bayesian forecasting algorithm allowing predictions of future doses, considering rifampicin's auto-induction, saturable pharmacokinetics and high interoccasion variability. METHODS: Rifampicin exposure targets for Bayesian dose optimisation were defined based on literature data on safety and anti-mycobacterial activity in relation to rifampicin's pharmacokinetics i.e. highest plasma concentration up to 24 hours and area under the plasma concentration-time curve up to 24 hours (AUC0-24h ). Targets were suggested with and without considering minimum inhibitory concentration (MIC) information. Individual optimal doses were predicted for patients treated with rifampicin (10 mg/kg) using the targets with Bayesian forecasting together with sparse measurements of rifampicin plasma concentrations and baseline rifampicin MIC. RESULTS: The suggested exposure target for Bayesian dose optimisation was a steady state AUC0-24h of 181-214 h × mg/L. The observed MICs ranged from 0.016-0.125 mg/L (mode: 0.064 mg/L). The predicted optimal dose in patients using the suggested target ranged from 1200-3000 mg (20-50 mg/kg) with a mode of 1800 mg (30 mg/kg, n = 24). The predicted optimal doses when taking MIC into account were highly dependent on the known technical variability of measured individual MIC and the dose was substantially lower compared to when using the AUC0-24h -only target. CONCLUSIONS: A new up-to-date exposure target for Bayesian dose optimisation suited for high-dose rifampicin was derived. Using measured plasma concentrations coupled with Bayesian forecasting allowed prediction of the future dose whilst accounting for the auto-induction, saturable pharmacokinetics and high between-occasion variability of rifampicin.
引用
- Svensson RJ, Niward K, Davies Forsman L, et al. Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis. Br J Clin Pharmacol. 2019. PMID: 31269277. doi:10.1111/bcp.14048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。